U.S. Other Utilities Stock News

Why Fulton Financial Is On Investors’ Radar Fulton Financial (FULT) has drawn attention after its recent share move, with the stock showing double digit gains over the past month and past 3 months, prompting closer scrutiny of its valuation and fundamentals. See our latest analysis for Fulton Financial. Fulton Financial’s recent gains build on earlier strength, with the share price at $22.75 and a 90 day share price return of 29.04% sitting alongside a 5 year total shareholder return of...

If you are wondering whether Victory Capital Holdings at US$71.25 is offering fair value or a potential bargain, you are in the right place because this article focuses squarely on what the current price might be implying. The stock has recent returns of 1.0% over 7 days, 7.9% over 30 days, 11.2% year to date and 3.9% over the past year, which raises the question of how these moves line up with what the business might be worth. Investors have been paying close attention to company specific...

Why Hut 8’s latest shift matters for shareholders Hut 8 (HUT) has moved into the spotlight after agreeing to a US$7b, 15-year data center lease with Fluidstack and arranging the sale of four Ontario natural gas power plants. For you as an investor, these paired moves put more focus on Hut 8’s role as a digital infrastructure and AI compute partner, and less on owning traditional power generation and purely Bitcoin mining assets. See our latest analysis for Hut 8. The stock has been volatile...

Diamondback Energy director Meloy Charles Alvin recently completed a significant sale of company shares, according to regulatory disclosures. The transaction involved a substantial number of NasdaqGS:FANG shares, drawing attention to insider trading activity at the oil and gas producer. Investors often watch large insider sales closely, as they can reflect how company insiders view the current share price or their personal exposure to the stock. Diamondback Energy, listed as NasdaqGS:FANG,...

If you are trying to figure out whether Bitmine Immersion Technologies at around US$20.47 is a bargain or a trap, you are in the right place for a clear look at what that price really implies. The share price has seen sharp swings, with a 7 day return of an 18.4% decline, a 30 day return of a 32.6% decline, a year to date return of a 34.4% decline, yet a 1 year return of a 192.5% gain. All of this raises questions about how much risk is now priced in. Recent news around the stock has...

Chemours stock snapshot after recent gains Chemours (CC) has caught investor attention after a recent run in its share price, with the stock up over the past week, month, past 3 months and year to date. See our latest analysis for Chemours. Chemours’ recent momentum has been strong, with a 30 day share price return of 40.17% and a year to date share price return of 49.55%, even though the 3 year total shareholder return sits at a 40.15% decline. If this kind of sharp rebound has your...

In early February 2026, Match Group reported fourth-quarter 2025 results that exceeded analyst expectations, raised its quarterly cash dividend to US$0.20 per share, and confirmed 2026 revenue guidance that points to relatively flat growth at the midpoint. Beneath the headlines, management highlighted improving user engagement from new Tinder features like DoubleDate and FaceCheck while continuing to return capital through buybacks and a higher dividend. Next, we’ll explore how Match Group’s...

If you are wondering whether Pfizer is genuinely good value or just looks cheap on the surface, this article walks through what the current numbers are really saying about the stock. Pfizer shares last closed at US$27.22, with returns of 3.0% over 7 days, 7.7% over 30 days, 8.1% year to date, 13.4% over 1 year, a 25.7% decline over 3 years and 0.6% over 5 years. Together, these figures give you a mixed picture of recent performance and shifting risk sentiment. Recent headlines around Pfizer...

Realty Income (O) has been back in focus after its first investment in Mexico, a partnership with Singapore’s GIC for logistics properties, and a large convertible notes deal to fund debt reduction and future growth. See our latest analysis for Realty Income. Those Mexico and logistics moves, along with the recent convertible notes issuance and analyst upgrades, have come alongside building momentum, with a 30 day share price return of 10.25% and a 1 year total shareholder return of...

NIO (NYSE:NIO) issued a profit alert for Q4 2025, guiding for its first ever adjusted operating profit. The company links the expected result to strong vehicle sales, a more favorable product mix, and cost reduction efforts. The alert marks a potential turning point in NIO's operating history and signals progress toward sustained profitability. NIO, an electric vehicle maker listed on the NYSE under the ticker NIO, is flagging a shift in its financial story with this profit alert for Q4...

Starwood Capital Group previously announced the appointment of John Gonnella as Senior Managing Director and Head of U.S. Asset Management, while Starwood Property Trust has drawn attention for offering a high dividend yield amid real estate sector volatility. Together, the leadership change at the broader Starwood platform and renewed focus on Starwood Property Trust’s dividend highlight how management execution and income appeal are central to investor interest in the mortgage REIT...

Western Midstream Partners overview Western Midstream Partners (WES) has drawn fresh investor attention as its unit price hovers near recent levels, with performance over the past year and longer term prompting renewed interest in its income and valuation profile. See our latest analysis for Western Midstream Partners. At a recent share price of US$41.12, Western Midstream Partners has seen mild pressure in the past week but still carries positive momentum on a 30 day and year to date share...

Recently, Chemed reported that its VITAS hospice unit had been hit by Medicare cap adjustments, softer patient admissions, and management turnover, prompting an earnings guidance revision. Amid these challenges, commentary around Chemed continues to emphasize the long-term structural appeal of the hospice market and the importance of VITAS’s recovery alongside the steadier Roto-Rooter business. Next, we’ll examine how the Medicare cap changes at VITAS influence Chemed’s broader investment...

Allegiant Travel Company reported fourth-quarter 2025 results on 4 February 2026, with revenue rising to US$656.19 million and net income of US$31.94 million, compared with a loss a year earlier. Management highlighted strong leisure demand, tighter cost control, and reaffirmed 2026 earnings guidance while preparing to integrate Boeing 737 MAX aircraft and the planned Sun Country acquisition. With recent strong earnings and a return to profitability, we'll now examine how Allegiant's 2026...

In late January 2026, Intellia Therapeutics reported that the FDA lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy, following protocol changes and enhanced liver safety monitoring. This decision allows Intellia to restart enrollment in a key late-stage program for a gene-editing therapy that aims to permanently inactivate the TTR gene, potentially reshaping treatment options...

Block (XYZ) is back in focus after rolling out Bitcoin payments for Square merchants and launching a second generation Square Register, while also attracting fresh capital from ARK Invest and renewed analyst attention. See our latest analysis for Block. Those product launches and crypto ties are arriving after a tough stretch, with a 30 day share price return showing a 21.69% decline and a 1 year total shareholder return showing a 34.40% loss, which points to fading momentum despite a recent...

Earnings momentum and guidance behind the latest interest in Viavi Solutions Viavi Solutions (VIAV) has moved into focus after its recent earnings report, where management highlighted revenue contributions from data center and aerospace and defense customers, along with guidance calling for third quarter net revenue of US$386 million to US$400 million. See our latest analysis for Viavi Solutions. Those earnings and the guidance appear to have shifted sentiment quickly, with the share price at...

MannKind Corporation previously announced that the FDA approved an update to Afrezza’s Prescribing Information, revising starting mealtime doses for adults switching from injected or pump-delivered insulin based on recent modeling and clinical data. This label change is noteworthy because it offers clearer conversion guidance for clinicians, potentially making transitions to Afrezza more clinically manageable while highlighting its pulmonary safety considerations. With this labeling update...

If you are wondering whether Cleveland-Cliffs is priced attractively right now, this article walks you through what the current share price might be implying about the company. The stock recently closed at US$14.73, with returns of 7.0% over 7 days, 22.3% over 30 days, 8.3% year to date and 46.7% over 1 year. The 3 year and 5 year returns stand at 26.1% and 11.3% declines respectively. These moves sit against a broader backdrop where investors continue to reassess US steel and iron ore...

Biogen's high dose nusinersen (SPINRAZA) regimen for spinal muscular atrophy has published new clinical results in Nature Medicine and is currently under FDA review. The FDA has granted Breakthrough Therapy Designation to litifilimab for cutaneous lupus erythematosus, highlighting another late stage program for the company. For investors watching Biogen (NasdaqGS:BIIB), these two updates come at a time when the stock is trading around $201.18. The share price reflects a mixed track record,...

If you are looking at United States Antimony and wondering whether the recent excitement lines up with its underlying value, you are not alone. The stock closed at US$8.61 recently, with returns of 17.5% over 7 days, 9.8% over 30 days, 45.2% year to date and 367.9% over 1 year, while the 3 year return is very large and the 5 year return stands at 441.5%. These moves have put the company back on the radar for investors who track materials and specialty metals stocks, especially given its...

Pure Storage has recently drawn heightened attention as investors focus on its strong earnings outlook, profitability, recurring long-term contracts, and expanding free cash flow, while the company also updates its partner programs to emphasize solutions-led engagement and managed services. A distinctive aspect of these developments is the new Ambassador partner tier, which targets highly skilled partners and could deepen adoption of Pure Storage’s data platform across key solution areas...

If you are wondering whether Select Medical Holdings is attractively priced today or if the current level already reflects its potential value, this article walks you through what the numbers are really saying about the stock. The share price most recently closed at US$15.69, with returns of 4.3% over 7 days, 3.2% over 30 days, 5.9% year to date, 6.4% over 3 years and 15.9% over 5 years, while the 1 year return of a 15.2% decline shows that shorter term sentiment has been weaker. Recent news...

Fair Isaac (NYSE:FICO) has entered a major global partnership with Tech Mahindra to expand AI powered decisioning solutions for BFSI clients worldwide. The partners are setting up a new Centre of Excellence to support deployment of Fair Isaac's platform and build industry specific use cases beyond traditional banking. The collaboration is aimed at helping financial institutions and other enterprises adopt AI driven decision tools at scale. Fair Isaac comes into this announcement with a...